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aternal perinatal mental health has enormous
consequences for the well-being of the mother, her baby,
and the family. Over the last decade there has been a
notable expanded awareness by health professionals and
the general public of the importance of maternal peri-
natal mental health, and acknowledgement of the preva-
lence and morbidity associated with psychiatric illness
during pregnancy and postpartum. Perinatal depression
is defined as an episode of major depressive disorder
(MDD) occurring either during pregnancy or within the
first 6 months postpartum, and is one of the most com-
mon complications of the both the prenatal and post-
partum period, with a prevalence of 10% to 15% in
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Maternal perinatal mental health has enormous consequences for the well-being of the mother, her baby, and the fam-
ily. Although it is well documented that perinatal depression is both common and morbid, with a prevalence of 10% to
15% in the general population, there remain many critically important unanswered questions about the pathogenesis
of perinatal depression and most effective treatment regimens. Current lines of evidence from both human and animal
models implicate hormonal dysregulation, abnormalities in hypothalamic-pituitary-adrenal axis activity, and the contri-
butions of genetics and epigenetics as playing key roles in the development of perinatal reproductive mood disorders.
Investigations into both human and animal models of perinatal depression offer much promise for the future identifi-
cation of the underlying pathophysiology and subsequent early identification and/or prevention and appropriate treat-
ment for women at risk for postpartum depression. Lastly, although it is generally accepted that pregnancy is not pro-
tective with regard to new onset or relapse of depression, the way to best treat maternal depression during pregnancy
and lactation remains hotly debated. Future research in this area will more clearly elucidate the underlying pathogene-
sis, the potential long-term impact of perinatal depression on the developing fetus, and how best to counsel pregnant
women about the risks of untreated major depressive disorder versus the risks of psychopharmacologic treatment dur-
ing pregnancy and lactation.      
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1,2 Consistent documentation
of the widespread prevalence of perinatal depression has
led to recent recommendations for routine screening
(“strongly encouraged but not mandated”) for both
antenatal and postpartum depression (PPD) by the
American College of Obstetricians and Gynecologists
(ACOG) Committee on Obstetric Practice in the US,
3,4
and the National Collaborating Center for Mental
Health in the UK.
5 Australia and New Zealand have
national recommendations stating that all perinatal
providers have the responsibility to be aware of the risks
for perinatal depression and to identify and refer for
treatment as indicated.
6 In Norway, the government has
endorsed an initiative to address mental health issues for
women during pregnancy and after childbirth.
7 In the
US, further evidence of support for perinatal depression
was the 2010 passage of the Melanie Blocker Stokes
MOTHERS Act, one component of the 2010 US Patient
Protection and Affordable Care Act (PPACA). The
MOTHERS act established a comprehensive federal
commitment to combat postpartum depression through
research, education, and voluntary support service pro-
grams. 
However, although considerable progress has been
made in terms of increasing public awareness, there
remain many critically important unanswered questions
and gaps in our understanding about perinatal depres-
sion. For example, there is still much to be learned about
the underlying pathogenesis, the long-term impact of
perinatal depression on the developing fetus, and how
best to counsel pregnant women about the risks of
untreated MDD versus the risks of psychopharmaco-
logic treatment during pregnancy and lactation. This
review will discuss these important issues and describe
currently recommended treatment options based on the
available literature. 
Epidemiology of perinatal depression
Many good quality studies have documented that peri-
natal depression is both common and morbid.
1,2,8-10
Estimates of prevalence are about 12% in the general
population, but higher in individuals from certain groups
including those with a prior history of MDD and in
those with a history of PPD.
2,10 In addition, an increased
prevalence has also been noted in low-income women,
which disproportionately affects ethnic minorities, par-
ticularly African-American and Hispanic women in the
US.
11,12 Moreover, the perinatal period has been docu-
mented to be a time of high risk for psychiatric hospi-
talization, particularly in women with bipolar affective
disorder and those with past histories of MDD.
13 Most
importantly, the risk for maternal suicide is significantly
elevated among depressed perinatal women, and mater-
nal suicides account for up to 20% of all postpartum
deaths, making it one of the leading causes of maternal
mortality in the perinatal period.
14
Perinatal depression can have devastating consequences
for the affected woman, her children, and family,
15-18 and
has been linked to poor childbirth outcomes such as
preterm delivery and low birth weight
19,20 and to detri-
mental effects on maternal sensitivity in the postpartum
period.
21,22 Mothers who are more sensitive and respon-
sive to their children are more likely to have children
with secure attachment, and therefore the symptoms of
maternal depression can lead to unresponsive, inconsis-
tent, unavailable, or rejecting care by the mother toward
the child (ie, decreased sensitivity).
21,22 Consequently,
depressed mothers are more likely to have infants with
colic,
23 to be intrusive and harsh with their infants,
21,22 and
to exhibit other impaired parenting behaviors such as
lower rates of infant safety practices
17,18 such as car seats
and childproof latches on cabinets,
24,25 and decreased
healthy child development behaviors such as reading,
singing, and playing games with their child.
26
Moreover, children exposed to perinatal (either during
pregnancy or postpartum) maternal depression have
higher cortisol levels than infants of mothers who were
not depressed
27-30 and this finding continues through ado-
lescence.
30 Importantly, maternal treatment of depres-
sion during pregnancy appears to help normalize infant
cortisol levels.
31These findings may partially explain the
mechanism for an increased vulnerability to psy-
chopathology in children of mothers with perinatal
depression.
32
Perinatal depression can also significantly impact the
relationship of the couple. Discord in the relationship
between mother and partner has been identified as an
important factor influencing both the development and
outcome of PPD.
33,34
Clinical presentation of perinatal depression
Mild mood and anxiety symptoms may be common
during pregnancy and throughout the first days to
weeks postpartum. In the early postpartum period,
Clinical research
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less are often called the “baby blues”; these symptoms
usually resolve spontaneously with no sequelae.
However, more severe and persistent mood and anxi-
ety symptoms should arouse suspicion of PPD. The
onset of PPD is usually within the first few months
after childbirth, although some women report onset of
symptoms during pregnancy. Distinguishing features of
PPD may include severe anxiety, agitation, suicidal
thoughts, and fears of hurting and/or lack of interest in
the newborn.
2 Ruminating and obsessive thoughts dur-
ing the perinatal period are increasingly documented
as a presenting complaint among many women seeking
treatment.
35,36
Pathogenesis of perinatal depression
Although the pathogenesis of perinatal depression is
currently unknown, it is an important area of ongoing
research. Investigations into both human and animal
models of perinatal depression offer much promise for
the future identification of the underlying pathophysi-
ology and subsequent early identification and/or pre-
vention and treatment for women at risk for PPD. We
will discuss current lines of evidence from both human
and animal models that implicate hormonal dysregula-
tion, abnormalities in hypothalamic-pituitary-adrenal
(HPA) axis activity, and the contributions of genetics and
epigenetics as playing key roles in the development of
perinatal reproductive mood disorders.
Dysregulation of the HPA axis in reproductive
endocrine mood disorders
The female reproductive steroid hormones, estrogen and
progesterone, are derived from a common precursor,
cholesterol. These hormones, in addition to their repro-
ductive functions, have been shown to exhibit potent
neuroregulatory effects on a range of nonreproductive
behaviors including mood and cognition.
37With the dis-
covery of the estrogen receptor in 1962 by Jensen and
Jacobson, a roadmap emerged for the cellular actions of
steroid hormones.
37,38 Moreover, beginning with the work
of Phoenix et al in 1959, there has been evidence to sug-
gest that perinatal manipulation of reproductive steroids
may have long-term consequences on brain sensitivity
to these to steroids postpuberty.
37,39 These two pieces of
animal model evidence laid the early framework which
implicated hormonal dysregulation in vulnerable or sus-
ceptible women as part of the underlying pathogenesis
of perinatal depression. 
More recent work by Block et al demonstrates that,
despite normal levels of reproductive hormones, women
with PPD have an abnormal response to changes in
reproductive steroid levels (estrogen and proges-
terone).
40Additionally, there is increasing evidence that
abnormalities in HPA axis activity play a key role in the
etiology of both MDD as well as PPD.
41-45 Estrogen and
progesterone have profound interactions with the HPA
axis and may therefore trigger the HPA axis abnormal-
ities in susceptible women. 
Striking hormonal changes take place in the transition
from pregnancy to the postpartum period.
46 The third
trimester of pregnancy is characterized by high estrogen
and progesterone levels and a hyperactive HPA axis
(normal during pregnancy) with high plasma cortisol
47
which is stimulated in part by the high levels of estrogen
and progesterone.
44At the time of childbirth and during
the transition to the postpartum period, estrogen and
progesterone rapidly decline, and there is blunted HPA
axis activity due to suppressed hypothalamic corti-
cotrophin-releasing hormone (CRH) secretion.
43 The
suppression may be due to the length of time it takes for
the hypertropic adrenal cortexes (due to the hyperstim-
ulated state during pregnancy), to progressively down-
size and gradually return to normal.
43 As in nonpuer-
peral MDD, the HPA axis appears disturbed in women
with PPD. Furthermore, although the trigger for PPD is
likely heritable, the human and animal literature suggest
that the onset of PPD is determined by the contributions
of both genetics and life events.
48,49 Thus, it is important
to briefly review the normal functioning of the HPA axis
and how this differs in depressed (non-PPD) patients as
compared with women with PPD. 
In a normal HPA axis, the delivery of CRH from the
paraventricular nucleus of the hypothalamus triggers the
stimulation of adrenocorticotropic hormone (ACTH)
from the anterior pituitary and, consequently, cortisol
from the adrenal cortex. This hormonal system is regu-
lated by negative feedback mediated by cortisol recep-
tors in the anterior pituitary, hypothalamus, and hip-
pocampus, as well as ACTH receptors in the anterior
pituitary and CRH autoreceptors in the hypothalamus.
50
In depressed patients, it has been shown that there is a
change in the regulation of the HPA axis.
51 A hallmark
feature that characterizes the HPA axis in depression is
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regulation: indeed, hyperactivity of the HPA axis is one
of the most robust biological findings in major depres-
sion.
51
Both women with PPD and women with nonpuerperal
MDD show abnormalities in HPA axis activity. In gen-
eral women (and men) suffering from MDD exhibit
high baseline cortisol and an exaggerated response to
the dexamethasone/corticotrophin-releasing hormone
(DEX/CRH) test. However, in the first few weeks post-
partum, euthymic women demonstrate an HPA axis
that remains refractory to external CRH challenge. In
contrast, women with PPD have been shown to experi-
ence an ongoing blunting of ACTH response to corti-
cotrophin-releasing hormone (CRH) at 6 to 12 weeks
postpartum compared with nondepressed women, inter-
preted as reflecting an ongoing hyporeactive HPA axis.
43
Additionally, Bloch et al observed that currently
euthymic women with a past history of PPD experi-
enced an increased cortisol response and onset of sig-
nificant depressive symptoms when exposed to a pro-
tocol consisting of high-dose gonadal steroid
administration followed by abrupt withdrawal. This
observed effect in those women with a history of PPD
was in marked contrast to the group of women without
a history of PPD who experienced no observed mood
disturbance when exposed to the same protocol. Thus,
this work suggests either a trait vulnerability related to
the onset of PPD or a consequence of an earlier depres-
sion.
45
Interestingly, the HPA axis has also been a focus of
recent efforts to identify a biomarker for those at risk
for perinatal or postpartum depression. In particular, ele-
vated placental CRH has been a potential candidate
with earlier literature demonstrating conflicting
results.
52,53 The increasing production of placental CRH
(pCRH) throughout pregnancy can be measured in
maternal peripheral blood
54 and within hours after child-
birth, levels of pCRH quickly drop and become unde-
tectable.
55 Nonetheless, the role of midpregnancy pCRH
as a biomarker of maternal prenatal and PPD does not
appear to be clinically useful, and the most recent report
did not demonstrate an association between increased
midpregnancy pCRH and increased risk for either
depression during pregnancy nor PPD.
56
Moreover, while the dysregulated HPA axis in PPD is
interesting, disturbances in other endocrine systems may
also play a role in the etiology of PPD. For example, one
study has demonstrated that women with antenatal total
and free thyroxine concentrations in the lower euthyroid
range may be at greater risk of developing postpartum
depressive symptoms.
57
Animal models of genetic and 
epigenetic transmission of maternal 
anxiety and depression to offspring 
In general, human studies of reproductive mood disor-
ders are complicated by a variety of factors including
lack of control over the subject’s environment and
genetic background, ethical issues of conducting
research in pregnant and postpartum women, and inac-
cessibility of brain tissue required for analysis in certain
studies. Therefore, animal models have been used suc-
cessfully to model perinatal maternal behavior and to
study the pathogenesis of perinatal anxiety, stress, and
depression. The elegant and groundbreaking work in
rodents by Meaney, Champagne, and colleagues
48,58 has
demonstrated that maternal behavior during both preg-
nancy and postpartum has profound effects on both the
physiological and psychological health of offspring. In
particular, traumatic experiences in early life may be
risk factors for the development of behavioral and emo-
tional disorders that persist into adulthood. Franklin
and colleagues recently reported that mice exposed to
chronic and unpredictable maternal separation in the
early postpartum period demonstrated depressive-like
behaviors and alterations in their behavioral response
to stressful environments when adults, particularly in
males.
59
Other recent animal literature demonstrates that mater-
nal psychological status, in particular anxiety and depres-
sion during and immediately after pregnancy, confers
increased vulnerability for mental illness in offspring.
Furthermore, perinatal maternal depression and anxiety
cause detrimental effects on maternal sensitivity, which
may result in impaired mothering behaviors associated
with insecure maternal/infant bonding and attachment.
48
Moreover, the consequences of impaired maternal-
infant attachment occurring at a critical time for infant
early brain development are serious and may lead to
detrimental effects on both infant brain morphology and
physiology, altered stress reactivity and socioemotional
and neurocogitive development, as well as long-term
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tural modification of chromosome regions leading to
changes in gene expression caused by a mechanism
other than changes in the DNA sequence, is a relatively
new area of intense study.
61 Although these molecular
changes involved in the epigenetics of the genome are
complex, there is one particular mechanism that is
thought to produce stable changes in gene expression.
There are specific sites where a methyl group can attach
to DNA via cytosine through an enzymatic reaction
called methylation.
62 At a most basic functional level,
methylation results in the silencing of the gene, and the
bond formed between the DNA cytosine and the methyl
group is strong, causing a stable but potentially
reversible change in gene expression.
63 However, DNA
methylation patterns can remain throughout the life of
the cell and may be passed along for multiple genera-
tions potentially causing the organism's genes to behave
differently, and providing an explanation for how early
life experiences can leave an indelible mark on the brain
and influence behavior and health in later life.
60 As an
illustration of the above description, recent ground-
breaking work in animal models of behavioral epige-
netics have documented changes in the methylation sta-
tus of individual genes in response to mothering
behavior.
58,60,64 For example, the observation that adult
behaviors in the rat could be influenced by the quality
of maternal care early in life
65 suggested an epigenetic
mechanism. Franklin and colleagues demonstrated in
rats that the stress of chronic and unpredictable early life
maternal separation in offspring altered the profile of
DNA methylation in the promoter of several candidate
genes in the germline of the separated males.
59
Additionally, Weaver, Champagne, and colleagues dis-
covered that poor maternal care directly increased
methylation in the promoter region of the glucocorticoid
receptor gene, effectively reducing the number of recep-
tors and resulting in heightened response to stress.
60
Methylation of the estrogen receptor (ER) alpha gene
has also been documented in rats who, as a product of
poor nurturing, go on to display poor maternal behav-
ior.
66 Specifically, Champagne et al demonstrated
increased methylation in response to maternal care in
the promoter region of the estrogen receptor (ER) alpha
gene which is implicated in induction of the oxytocin
gene.
66 The oxytocin gene codes for the oxytocin hor-
mone which promotes mother-infant attachment and
affects maternal behavior. 
Therefore, although behavioral epigenetics is a new area
of study that offers an opportunity to define the nature
of gene-environment interactions during development,
there is much that remains unknown and future research
is needed in order to disentangle the genetic, environ-
mental, and epigenetic mechanisms that mediate mater-
nal behavior and subsequent infant outcomes. 
Controversies in the treatment of depression
during pregnancy and postpartum
Although it has become generally accepted knowledge
that pregnancy is not protective with regard to new
onset or relapse of MDD,
67,68 how best to treat depres-
sion during pregnancy and lactation remains hotly
debated. Nonetheless, despite the ongoing controversies
surrounding treatment, psychotropic use during preg-
nancy has become relatively common with a two- to
fourfold increase in use over the past decade despite a
stable prevalence of psychiatric illness.
69,70 Moreover,
recent reports have documented that up to 13% of all
pregnant women are using an antidepressant during
pregnancy.
70 In particular, the selective serotonin reup-
take inhibitors (SSRIs) are the first-line, most frequently
used antidepressants among pregnant women
70,71 The
choice of whether to prescribe a medication during preg-
nancy is a difficult one, and prescribing must take into
account the potential risks and benefits to the unborn
infant and the mother. To date, the literature on the
safety of antidepressants during pregnancy has yielded
conflicting results that can be difficult to apply toward
practical clinical recommendations. As elegantly stated
by Rubinow in his 2006 American Journal of Psychiatry
editorial on antidepressant treatment of pregnant
women, “our therapeutic confusion derives in part from
the requirement to calculate risk profiles for two indi-
viduals (mother and infant), involving multiple predic-
tors and outcomes.”
72 Unfortunately, calculation of risk
based on high-quality studies is challenging because
research focused on women during pregnancy or post-
partum (and during lactation) present substantial ethi-
cal and practical challenges for the investigator, thus
compromising the rapid accumulation of reliable data.
73
However, despite the absence of a large evidence base
to guide treatment recommendations, the clinician must
carefully discuss treatment options with the woman suf-
fering from perinatal depression so that an understand-
ing of the risk:benefit ratio of treatment versus no treat-
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depressant medication during pregnancy or lactation
must be weighed against the risks of untreated maternal
depression and this risk:benefit ratio must be carefully
discussed and tailored to the individual needs with each
patient. A recent and helpful development in the cre-
ation of evidence-based practice guidelines for perina-
tal depression was the 2009 publication by Yonkers et al:
a joint report on the management of depression during
pregnancy endorsed by the American Psychiatric
Association (APA) and the American College of
Obstetricians and Gynecologists (ACOG) and published
simultaneously in both General Hospital Psychiatry and
Obstetrics and Gyencology.
74,75This report represents the
first time that the APA and ACOG have collaborated to
create practice guidelines for clinicians, and as such, sig-
nifies a significant contribution to the field. The report
states that both MDD and antidepressant exposure are
associated with fetal growth changes and shorter gesta-
tions, and that the current literature was unable to con-
trol for the possible effects of a depressive disorder in
women and their infants exposed to an antidepressant
during pregnancy (thus complicating interpretation of
the risks associated with antidepressant use during preg-
nancy).
75
Weighing risks and benefits of 
antidepressants during pregnancy
There are significant risks associated with exposure to
untreated depression during pregnancy that are asso-
ciated with serious adverse consequences for the
developing neonate, such as premature birth, low birth
weight, and future behavioral disturbances.
76,77 Studies
have shown that terminating antidepressant treatment
in pregnancy in women with a previous history of
depression leads to relapse of symptoms in as many as
60% to 70% of women.
67,68 Relapse then exposes the
developing infant to the effects of untreated depres-
sion, which has potentially devastating consequences
for the patient, infant, and family. Untreated depres-
sion during pregnancy is also one of the strongest risk
factors for the development of PPD. However, mater-
nal antidepressant use during pregnancy has been
associated with documented risks to exposed infants
including persistent pulmonary hypertension of the
newborn (PPHN) and a neonatal withdrawal/toxicity
syndrome. 
Persistent pulmonary hypertension
PPHN is a failure of the pulmonary vasculature to
decrease resistance at birth. This results in significant
breathing difficulties for the infant, hypoxia, and usually
leads to intubation. PPHN has about a 10% to 20% mor-
tality rate, and also results in significant morbidity.
78 It is
a very rare condition, affecting 1 or 2 infants out of 1000
in the general population,
79,80 and has been associated
with a number of factors including maternal smoking,
81
maternal diabetes, sepsis, meconium aspiration, and C-
section, among others.
80
Studies on the association between SSRIs and PPHN
have yielded conflicting results, although more recent
studies suggest the risk for PPHN following SSRI use
during pregnancy is far less than originally estimated. The
first report was published by Chambers et al in 2006 and
is the basis for the FDA alert issued in July 2006 regard-
ing the possible association of PPHN with SSRI antide-
pressants.
82A second study was conducted through the
Swedish Medical Birth Register for the years 1997 to
2005 and examined 831 324 women who had given birth
during this time.
83Antidepressant use was identified at
the first antenatal care visit (usually first trimester) and
through prescriptions written by the antenatal health ser-
vice. Of 506 infants with PPHN, 11 had been exposed
early in pregnancy to an SSRI which generated a relative
risk estimate of 2.01 (CI 1.00-3.60). When only those
cases that had a known exposure late in pregnancy and
were born at or after 37 weeks were included the relative
risk rose to 3.70 (CI 1.01-9.48).
83 More recently, a study
from the HMO Research Network Center for Education
and Research on Therapeutics found no differences
between groups in prevalence of PPHN between infants
exposed versus those not exposed to SSRIs during the
third trimester.
71 One issue that complicates interpreta-
tion of these studies is that several factors that are asso-
ciated with the development of PPHN in the general
population, including maternal smoking, maternal dia-
betes, and high prepregnancy BMI are also associated
with MDD and psychiatric disorders in general. It is also
important to keep the potential elevated risk in perspec-
tive by considering the absolute risk. If one assumes that
SSRIs increase the odds of the development of PPHN 6
times the rate in the general population, only 6 to 12
(0.6% to 1.2%) infants exposed to SSRIs will develop
PPHN out of 1000 exposed. Thus, approximately 99% of
women who take SSRIs during pregnancy will give birth
Clinical research
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trast, the risks associated with untreated depression dur-
ing pregnancy are much higher and more frequent.
72
Withdrawal/toxicity symptoms
The first report of withdrawal symptoms in babies
exposed to antidepressants occurred in 1973.
84 It is unclear
if “neonatal withdrawal syndrome” is actually a result of
withdrawal from the antidepressant medication or is due
to a toxicity mechanism. Thus, an alternative term such as
“poor neonatal adaptation,” or “neonatal neurobehav-
ioral syndrome” may be a better description. Although
there are a number of limitations in the available litera-
ture in this area, including inconsistent definitions, regard-
less, the FDA instituted a class labeling change in 2004 for
both SSRI and SNRI (serotonin-norepinephrine reuptake
inhibitors) antidepressants warning that third trimester
exposure to antidepressants may be associated with signs
and symptoms consistent with the syndrome. According
to the label change, “reported clinical findings have
included respiratory distress, cyanosis, apnea, seizures,
temperature instability, feeding difficulty, vomiting, hypo-
glycemia, hypotonia, hypertonia, hyperreflexia, tremor,
jitteriness, irritability, and constant crying.” The subse-
quent result has been that many practitioners have rec-
ommended tapering antidepressants prior to labor and
delivery even though most cases of the neonatal syn-
drome appear to be very mild, self-limited, and do not
appear to be associated with lasting repercussions
85
Recently, investigators in British Columbia studied
whether adverse neonatal outcomes were reduced by
stopping SSRI use before the end of pregnancy in a large
cohort study that linked maternal health and prenatal
SSRI prescription claims data to more than 119 000
neonatal birth records.
86After controlling for possible con-
founding factors, including severity of maternal illness, the
results showed neonatal outcomes did not improve when
SSRI medications were stopped before the last 2 weeks
of gestation and provided evidence that some adverse
neonatal outcomes may not be consequent to an acute
pharmacological condition such as toxicity or with-
drawal.
86 Oberlander and Gingrich have reported on ani-
mal model literature describing neurobehavioral conse-
quences of prenatal SSRI exposure.
87This preclinical work
shows that in animal models, early changes in serotoner-
gic tone have molecular, neuroanatomical,and functional
consequences, which are dependent on the timing (criti-
cal periods) and direction (increased or decreased) of
change.
87 Clearly, larger, prospective human studies of the
syndrome as well as strategies to minimize the incidence
rate of the syndrome are needed. However, to date, there
is no evidence from a safety perspective to recommend
tapering of antidepressants in the third trimester, partic-
ularly in cases of moderate to severe maternal mental ill-
ness. Keeping the mother psychiatrically well should be
the overarching goal of treatment during pregnancy for
both the mother and the baby. In addition, the literature
clearly documents that untreated depression in pregnancy
carries a 6-fold increased risk for postpartum depression.
88
Specific antidepressants and pregnancy
In general, many practitioners will prescribe SSRI med-
ications during pregnancy since they are well-tolerated.
Overall, with one exception (paroxetine), there does not
appear to be an increased risk of major malformations
with exposure to antidepressants in utero, though for
many agents there is little to no data available.
75,89,90 More
recently, some studies have not confirmed the earlier
reports of increased risks of cardiac septal defects asso-
ciated with paroxetine and some studies have found very
weak associations with septal defects for both sertraline
and citalopram.
91 However, overall, of the SSRI medica-
tions, both fluoxetine
92,93 and sertraline
93,94 have more data
regarding safety than the newer SSRIs such as escitalo-
pram and the SNRIs.
75,89,93,94As first trimester exposure to
paroxetine has been associated with cardiac defects in
some studies, but not all, it should not be used as a first-
line agent, but may be considered if the patient has
responded well in the past.
4,74 The older tricyclic antide-
pressants should also be considered for use during preg-
nancy if they have been efficacious for the patient in the
past, though side effects, particularly constipation and
orthostatic hypotension, may be exacerbated by preg-
nancy.
75There is limited data on the use of SNRIs, bupro-
pion, mitazapine, and monoamine oxidase inhibitors,
although reported risks appear to be small and these
agents may be appropriate in a particular patient if they
have been efficacious in the past.
74
Antidepressant use in the postpartum 
period and during lactation
In the postpartum period,the literature demonstrates
that women with PPD are likely to respond to standard
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medication has not been proven to be superior to
another.
95 The risks of exposure to antidepressant ther-
apy in the postpartum period are primarily focused on
the exposure of the infant to the antidepressant in breast
milk.
95 Most of the literature examining the safety of lac-
tation with antidepressant use has found low rates of
adverse events in infants exposed to antidepressants,
including tricyclics and SSRIs.
95 In particular, most stud-
ies show few adverse events and low or undetectable
plasma levels with sertraline, paroxetine, and fluvoxam-
ine.
96 Sertraline, in particular, appears to have the lowest
concentration of transmission into breast milk and
should be strongly considered as first line use for lacta-
tion.
93,95 The long half-life of fluoxetine and the poten-
tially high breast milk concentrations of citalopram
make these SSRIs less desirable choices.
96 Overall, the
degree of infant exposure to medication in breast milk
is affected by the rate of absorption into maternal cir-
culation, diffusion from maternal circulation to breast
milk, and absorption of the agent by the infant.
Therefore, as a general recommendation, taking med-
ication immediately after breast-feeding minimizes the
amount present in milk and maximizes clearance before
the next feeding.
97
Regarding lactation, in the United States, all major
medical organizations recommend exclusive breast-
feeding for the first 6 months of life including The
American Academy of Pediatrics
98 and The American
College of Obstetrics and Gynecology.
99 Consequently,
although 75% of mothers initiate breastfeeding, only 
12 continue to breastfeed exclusively through 6
months.
100,101 Much of this early weaning is involuntary:
in a recent study, more than half of mothers reported
that they stopped breastfeeding earlier than they had
desired.
102 Curtailed breastfeeding is associated with
maternal depression, and neuroendocrine pathways
underlying both lactation and regulation of maternal
mood may play a central role.
Psychotherapy during pregnancy and postpartum 
There are multiple psychotherapeutic techniques, includ-
ing individual cognitive behavioral therapy (CBT) or
interpersonal psychotherapy (IPT), as well as group
therapy that may be helpful in patients with mild-to-
moderate depression.
75,103,104 IPT for pregnant and post-
partum women has been shown to ameliorate depres-
sion during pregnancy and postpartum.
104-107 In addition,
partner-and family-assisted therapies have shown effi-
cacy for the treatment of perinatal depression.
108 Some
women with mild-to-moderate symptoms of depression
may prefer a psychotherapeutic treatment option to the
risks of medication exposure. For women with more
severe symptoms of depression, a combination treat-
ment approach consisting of psychotherapy and med-
ication may be the best option.
Practical guidelines and clinical recommendations 
A collaborative and multidisciplinary treatment
approach with the psychiatrist, obstetrician, and pedia-
trician is critical in order to educate the patient about
both the risks of untreated depression and potential side
effects to mother and baby associated with psychotropic
exposure during pregnancy and/or lactation. Some prac-
tical guidelines (Table I) for counseling the patient in
order to ensure optimal outcomes include the following:
(i) A past psychiatric history should always be obtained
as it will influence the selection of the treatment modal-
ity. The psychiatric history should include any prior
episodes of depression, a history of hypomanic or manic
episodes, severity of those episodes, potential triggers of
mania including past antidepressant exposure, timing
(prior PPD), as well as treatment history and documen-
tation of prior response to antidepressant medication;
(ii) Minimize the number of exposures for the baby. It is
important to minimize the number of psychotropic med-
ications used but also consider exposure to psychiatric
illness an exposure. Changing the medications used dur-
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￿ A multidisciplinary team approach is best to maximize outcomes
￿ Obtain a careful and thorough past psychiatric history
￿ All medication changes should be done prior to pregnancy if 
possible
￿ Limit the number of exposures for the baby; consider active 
depression in the mother an exposure
￿ Prescribe medications with the best documented evidence base 
￿ Consider whether the mother plans to breastfeed when 
planning treatment
￿ If a baby was exposed to a medication during pregnancy, it may 
not make sense to discontinue the medication (or alternatively 
not breastfeed)
￿ Discuss psychotherapy as a treatment option
Table I. Practical guidelines for treating depression during pregnancy and
postpartum.
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ing pregnancy into the postpartum period when breast-
feeding increases the number of exposures. For example,
it is common for a woman on a newer antidepressant to
become pregnant and then to receive the recommenda-
tion to switch antidepressants to an older medication
that has more evidence for safety during pregnancy.
While this might have made sense prior to pregnancy,
this plan would actually increase the exposures for the
baby. First, the baby has already been exposed to the
newer antidepressant, and switching to a second med-
ication would be another exposure. In addition, the like-
lihood that the patient could relapse while switching is
high, thus exposure to the mood disorder would be a
third exposure for the child; (iii) Consider whether the
mother plans to breastfeed and discuss whether the
medication can be safely used during breastfeeding and
what the plan would be for monitoring the medication
during breastfeeding; (iv) Discuss psychotherapy treat-
ment options.
Conclusions
Perinatal depression is often debilitating to the woman
experiencing it and to her family. Screening must be a
routine part of postpartum care as there are effective
treatments available that can prevent needless suffering.
Although the etiology of perinatal depression remains
unclear, headway is being made toward a better under-
standing of the complicated interplay of reproductive
steroids (estrogen and progesterone) with the HPA axis
and other neuroregulatory systems implicated in depres-
sive illness. Further study of the alterations in the HPA
axis during the transition from pregnancy to the post-
partum period may provide new insights into the patho-
physiology of perinatal mood disturbances. Animal stud-
ies have been used successfully to model perinatal
maternal behavior and to study the pathogenesis of peri-
natal anxiety, stress, and depression. In addition, the
rapidly growing field of behavioral epigenetics offers an
intriguing area of study that may provide new insights
into the nature of gene-environment interactions during
development. Future research will help to disentangle
the complex genetic, environmental, and epigenetic
mechanisms that mediate maternal mental illness dur-
ing the perinatal period including the subsequent influ-
ence on maternal behavior and infant outcomes. 
Regarding treatment of depression during pregnancy,
antidepressant use in pregnant women is often necessary
in order to prevent maternal psychiatric illness. Recent
collaborative consensus statements by the American
Psychiatric Association and the American College of
Obstetricians and Gynecologists provide a useful frame-
work for the interpretation of data about the safety of
psychotropic medications during pregnancy and lacta-
tion. Therefore, individualized recommendations based
on the patient’s past history should ideally be imple-
mented prior to pregnancy with a goal of minimizing
exposures.
In the postpartum period, commonly prescribed antide-
pressant medications used to treat PPD appear to be
well tolerated by both nursing mothers and their infants
and rates of adverse events are low. However, the baby
will be exposed to the antidepressant in breast milk, and
therefore, the patient and her partner should discuss
both the risks versus benefits of lactation with their
obstetrician and pediatrician. 
Finally, it is critical that more research is conducted in
the area of perinatal psychiatry in order to address the
gaps in the literature, including: (i) prospective studies
that further our understanding of the safety of antide-
pressant exposure in pregnancy and during lactation; (ii)
longitudinal neurodevelopmental studies of children
exposed to maternal mental illness, with or without psy-
chotropics during pregnancy; and (iii) translational
research that elucidates the underlying the pathophysi-
ology of perinatal reproductive mood disorders with the
long-term goal of ensuring the best possible clinical out-
comes for mother and child. ❏
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